Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy ... the cGAS-STING signaling pathway, a key player in innate immune activation.

Prof. WU Zhengyan from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, in collaboration with ...

Tumor Model of Colorectal Cancer (CRC),” TP-317 demonstrated potent anti-tumor activity and synergy with checkpoint inhibitors. Key findings include: TP-317 activated STING and IFN-γ pathways ...

Nine researchers from Utrecht have received funding in the 25th round of the NWO Open Competition ENW-XS. The grants (of up to 50,000 euros) are intended to enable small-scale, innovative and risky ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

"2'3'-cGAMP has been tested to enhance cancer immunotherapy ... 2'3'-cGAMP could also activate Rab18/FosB signaling pathway—but not the well-studied 2'3'-cGAMP/STING signaling pathway—to ...

They found that a STING agonist can reactivate these pathways in breast cancer cells, but it also does so in normal cells, suggesting that this is not a good way to create a therapeutic window.

Notably, high SMB melanoma tumors deficient in STING expression escaped immune control by reducing infiltration and activation ... cancer cells as a critical factor for tumor immunogenicity and should ...

Gut microbiota and its primary metabolite, butyrate, have been reported to potentially modulate tumor sensitivity to chemotherapy or immunotherapy ... I expression on tumor cells through activation of ...